Continuation of Tyrosine Kinase Inhibitor is Associated with Survival Benefit in NSCLC Patients with Exon 19 Deletion after Solitary Progression.

J Cancer · 2017 · PMC5688921 · PMID 29151955

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Interestingly, its subgroup analysis showed a trend toward a longer second PFS in patients with exon 19 deletion over L858R mutation, but overall survival result has not been reported.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.